Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cholesterol cream repair the skin barrier better than standard urea cream?

NCT ID NCT07689435

Disease control Sponsor: Institute of Dermatology, Thailand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a cream containing 10% cholesterol improves skin barrier function and quality of life more than a standard 10% urea cream in people with autosomal recessive congenital ichthyosis (ARCI), a rare genetic condition causing dry, scaly skin. Each participant applies one cream to one side of the body and the other cream to the opposite side, allowing direct comparison. Researchers measure skin water loss, hydration, dryness, itching, and quality of life over the treatment period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
10% cholesterol cream
What this could lead to
If cholesterol cream works better, it could offer a more targeted way to repair the skin barrier in people with ARCI, potentially reducing dryness and itching more effectively than current standard care.
What could go wrong
This is a small, early-stage study with only 24 participants, so results may not apply to everyone. Cholesterol cream might not outperform urea cream, or could cause skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients aged 7 to 65 years 2. Confirmed diagnosis of Autosomal Recessive Congenital Ichthyosis (ARCI), established by history, family/genetic history, clinical presentation, and/or genetic testing 3. Disease activity stable (not in an acute flare) 4. Thai nationality 5. Receiving care at the Institute of Dermatology 6. Willing and able to provide informed consent (or, for participants under 18, assent with parental/legal guardian consent) Exclusion Criteria: 1. Presence of any other concurrent skin disease 2. Known history of allergy to any component of the study creams 3. Active skin infection (e.g., herpes zoster, viral, fungal, bacterial, or parasitic infection) 4. History of any malignancy 5. Pregnant (confirmed by positive urine pregnancy test), breastfeeding, or planning pregnancy during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autosomal recessive congenital ichthyosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal recessive congenital ichthyosis inherited ichthyosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autosomal recessive congenital ichthyosis Ichthyosis inherited Skin barrier dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of dermatology

    Bangkok, Bangkok, 10330, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.